Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
WATERTOWN, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. NASDAQ:TECX (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors…